Rivastigmine
Active ingredient: Rivastigmine
In short: Rivastigmine transdermal system is indicated for the treatment of dementia of the Alzheimer's type (AD). Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's disease.
What is Rivastigmine used for?
Rivastigmine transdermal system is indicated for the treatment of dementia of the Alzheimer's type (AD). Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's disease.
Rivastigmine transdermal system is indicated for the treatment of mild-to-moderate dementia associated with Parkinson's disease (PDD).
Rivastigmine dosage
Initial Dose
Initiate treatment with one 4.6 mg/24 hours rivastigmine transdermal system applied to the skin once daily .
Dose Titration
Increase the dose only after a minimum of 4 weeks at the previous dose, and only if the previous dose has been tolerated. For mild-to-moderate AD and PDD patients, continue the effective dose of 9.5 mg/24 hours for as long as therapeutic benefit persists. Patients can then be increased to the maximum effective dose of 13.3 mg/24 hours dose. For patients with severe AD, 13.3 mg/24 hours is the effective dose. Doses higher than 13.3 mg/24 hours confer no appreciable additional benefit, and are associated with an increase in the incidence of adverse reactions .
Mild-to-Moderate Alzheimer's Disease and Mild-to-Moderate Parkinson's Disease Dementia
The effective dosage of rivastigmine transdermal system is 9.5 mg/24 hours or 13.3 mg/24 hours administered once per day; replace with a new transdermal system every 24 hours.
Severe Alzheimer's Disease
The effective dosage of rivastigmine transdermal system in patients with severe Alzheimer's disease is 13.3 mg/24 hours administered once per day; replace with a new transdermal system every 24 hours.
Interruption of Treatment
If dosing is interrupted for 3 days or fewer, restart treatment with the same or lower strength rivastigmine transdermal system. If dosing is interrupted for more than 3 days, restart treatment with the 4.6 mg/24 hours rivastigmine transdermal system and titrate as described above.
Dosing Modifications in Patients with Hepatic Impairment
Consider using the 4.6 mg/24 hours rivastigmine transdermal system as both the initial and maintenance dose in patients with mild (Child-Pugh score 5 to 6) to moderate (Child-Pugh score 7 to 9) hepatic impairment .
Dosing Modifications in Patients with Low Body Weight
Carefully titrate and monitor patients with low body weight (less than 50 kg) for toxicities (e.g., excessive nausea, vomiting), and consider reducing the maintenance dose to the 4.6 mg/24 hours rivastigmine transdermal system if such toxicities develop.
Patients treated with rivastigmine capsules or oral solution may be switched to rivastigmine transdermal system as follows:
A patient who is on a total daily dose of less than 6 mg of oral rivastigmine can be switched to the 4.6 mg/24 hours rivastigmine transdermal system.
A patient who is on a total daily dose of 6 mg to 12 mg of oral rivastigmine can be switched to the 9.5 mg/24 hours rivastigmine transdermal system.
Instruct patients or caregivers to apply the first transdermal system on the day following the last oral dose.
Rivastigmine transdermal system is for transdermal use on intact skin. …
How to take Rivastigmine — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Importance of Correct Usage
Inform patients or caregivers of the importance of applying the correct dose on the correct part of the body. They should be instructed to rotate the application site in order to minimize skin irritation. The same site should not be used within 14 days. The previous day's transdermal system must be removed before applying a new transdermal system to a different skin location. Rivastigmine transdermal system should be replaced every 24 hours and the time of day should be consistent. It may be helpful for this to be part of a daily routine, such as the daily bath or shower. Only 1 transdermal system should be worn at a time .
Instruct patients or caregivers to avoid exposure of the transdermal system to external heat sources (excessive sunlight, saunas, solariums) for long periods of time.
Instruct patients who have missed a dose to apply a new transdermal system immediately. They may apply the next transdermal system at the usual time the next day. Instruct patients to not apply 2 transdermal systems to make up for 1 missed. …
Warnings & precautions
Do not take this medicine if: Rivastigmine transdermal system is contraindicated in patients with:
known hypersensitivity to rivastigmine, other carbamate derivatives, or other components of the formulation .
previous history of application-site reactions with rivastigmine transdermal system suggestive of allergic contact dermatitis .
Isolated cases of generalized skin reactions have been described in postmarketing experience .
Medication errors with rivastigmine transdermal system have resulted in serious adverse reactions; some cases have required hospitalization, and rarely, led to death. The majority of medication errors have involved not removing the old transdermal system when putting on a new one and the use of multiple transdermal systems at one time.
Instruct patients and their caregivers on important administration instructions for rivastigmine transdermal system .
Rivastigmine transdermal system can cause gastrointestinal adverse reactions, including significant nausea, vomiting, diarrhea, anorexia/decreased appetite, and weight loss. Dehydration may result from prolonged vomiting or diarrhea and can be associated with serious outcomes. The incidence and severity of these reactions are dose-related . For this reason, initiate treatment with rivastigmine transdermal system at a dose of 4.6 mg/24 hours and titrate to a dose of 9.5 mg/24 hours and then to a dose of 13.3 mg/24 hours, if appropriate .
If treatment is interrupted for more than 3 days because of intolerance, reinitiate rivastigmine transdermal system with the 4.6 mg/24 hours dose to reduce the possibility of severe vomiting and its potentially serious sequelae. A postmarketing report described a case of severe vomiting with esophageal rupture following inappropriate reinitiation of treatment of an oral formulation of rivastigmine without retitration after 8 weeks of treatment interruption. …
Rivastigmine side effects
The following clinically significant adverse reactions are described below and elsewhere in the labeling:
Gastrointestinal Adverse Reactions
Skin Reactions
Other Adverse Reactions from Increased Cholinergic Activity
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Rivastigmine transdermal system has been administered to 4516 patients with Alzheimer's disease during clinical trials worldwide. Of these, 3005 patients have been treated for at least 26 weeks, 1771 patients have been treated for at least 52 weeks, 974 patients have been treated for at least 78 weeks, and 24 patients have been treated for at least 104 weeks.
Mild-to-Moderate Alzheimer's Disease
24-Week International Placebo-Controlled Trial (Study 1)
Most Common Adverse Reactions
The most common adverse reactions in patients administered rivastigmine transdermal system in Study 1 , defined as those occurring at a frequency of at least 5% in the 9.5 mg/24 hours rivastigmine transdermal system arm and at a frequency at higher than in the placebo group, were nausea, vomiting, and diarrhea. These reactions were dose-related, with each being more common in patients using the unapproved 17.4 mg/24 hours rivastigmine transdermal system than in those using the 9.5 mg/24 hours rivastigmine transdermal system. …
Drug interactions
Due to the risk of additive extra-pyramidal adverse reactions, the concomitant use of metoclopramide and rivastigmine transdermal system is not recommended.
Rivastigmine transdermal system may increase the cholinergic effects of other cholinomimetic medications and may also interfere with the activity of anticholinergic medications (e.g., oxybutynin, tolterodine). Concomitant use of rivastigmine transdermal system with medications having these pharmacologic effects is not recommended unless deemed clinically necessary .
Additive bradycardic effects resulting in syncope may occur when rivastigmine is used concomitantly with beta-blockers, especially cardioselective beta-blockers (including atenolol). Concomitant use is not recommended when signs of bradycardia including syncope are present.
About this medicine
Rivastigmine transdermal system contains rivastigmine USP, a reversible cholinesterase inhibitor known chemically as (S)-3-[1-(dimethylamino)ethyl]phenyl ethylmethylcarbamate. It has an empirical formula of C14H22N2O2 as the base and a molecular weight of 250.34 g/mol (as the base). Rivastigmine is a viscous, clear, and colorless to yellow to very slightly brown liquid that is sparingly soluble in water and very soluble in ethanol, acetonitrile, n-octanol and ethyl acetate.
The distribution coefficient at 37°C in n-octanol/phosphate buffer solution pH 7 is 4.27.
Rivastigmine transdermal system is for transdermal administration. The transdermal system is a four-layer laminate containing (1) a foam backing with adhesive layer, (2) a polyester film, (3) an adhesive matrix containing rivastigmine, and (4) a fluoropolymer coated polyester release liner . The release liner is removed and discarded prior to use. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 8b809739-8381-4cc1-ab4a-5b17ab902a3d. Read the full official label on DailyMed.